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Background: Psychosis is associated with both dysglycaemia 
and low-grade inflammation, but population-based studies 
investigating the interplay between these factors are scarce. 
Aims: (1) To explore the direction of association between 
markers of dysglycaemia, inflammation and psychotic experi-
ences (PEs); and (2) To explore whether dysglycaemia mod-
erates and/or mediates the association between inflammation 
and PEs.  Method: Data from the Avon Longitudinal Study of 
Parents and Children (ALSPAC) birth cohort were modeled 
using logistic and linear regression to examine cross-sectional 
and longitudinal associations between markers of dysglycae-
mia (ages 9 and 18), interleukin-6 (IL-6) (age 9), and PEs 
(ages 12 and 18). We tested for an interaction between dysgly-
caemia and IL-6 on risk of PEs at age 18, and tested whether 
dysglycaemia mediated the relationship between IL-6 and 
PEs.  Results: Based on 2627 participants, at age 18, insulin 
resistance (IR) was associated with PEs (adjusted OR = 2.32; 
95% CI, 1.37–3.97). IR was associated with IL-6 both cross-
sectionally and longitudinally. Interaction analyses under a 
multiplicative model showed that IR moderated the associa-
tion between IL-6 at age 9 and PEs at age 18 (adjusted OR 
for interaction term = 2.18; 95% C.I., 1.06–4.49). Mediation 
analysis did not support a model of IR mediating the rela-
tionship between IL-6 and PEs.  Implications: IR is associ-
ated with PEs in young people even before the onset of clinical 
psychosis. Metabolic alterations may interact with childhood 
inflammation to increase risk of PEs. The findings have impli-
cations for clinical practice and future research.
Key words:  dysglycaemia/insulin resistance/psychosis/ 
risk/schizophrenia/inflammation/ALSPAC
Introduction
It is over 100 years since Henry Maudsley first reported 
an association between dysglycaemia and psychotic 
illness1 (then dementia praecox), decades before the 
advent of  antipsychotic medication. Further corrobo-
rative reports2–4 in the pre-antipsychotic era supported 
this association, but these have been often overlooked 
after the detrimental effects of  antipsychotics on meta-
bolic indices were discovered.5,6 Recent meta-analyses 
have found sensitive measures of  dysglycaemia (insulin 
resistance [IR], impaired glucose tolerance [IGT] and 
fasting insulin [FI]) to be associated with first-episode 
psychosis (FEP), independent of  antipsychotic use and 
sociological/anthropomorphic factors,7,8 suggesting 
that the association between dysglycaemia and psycho-
sis extends beyond the effects of  antipsychotic medica-
tion, reduced access to healthcare and lifestyle factors. 
However, most research in the field has been cross-
sectional, with little exploration of  the longitudinal 
association between dysglycaemia and psychosis risk. 
Glycaemia exists on a continuum, as do psychoses.9 
Examination of  the relationship between dysglycae-
mia and psychotic experiences (PEs) in young people 
may provide evidence for an association unbiased by 
antipsychotic medication, chronicity of  illness, physi-
cal comorbidities, and smoking, alcohol and other life-
style factors.
A potential role of the immune system in the patho-
genesis of psychosis has been proposed10 and low-grade 
systemic inflammation may link dysglycaemia and psy-
chosis in a subgroup of patients. Evidence indicates that 
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inflammatory cytokines such as interleukin-6 (IL-6) and 
tumor necrosis factor alpha (TNF-α) contribute to the 
pathogenesis of glycaemic dysfunction.11–13 Additionally, 
elevated concentrations of C-reactive protein (CRP), 
IL-6, and other inflammatory markers are also elevated 
in patients with established schizophrenia14 and unmedi-
cated FEP,15 and research from large birth cohorts has 
reported that increased levels of IL-6 and CRP during 
childhood and adolescence are associated with subse-
quent PEs and a diagnosis of schizophrenia.16,17 A func-
tional variant in the IL-6R gene, which is known to 
dampen inflammation, is protective for psychosis,18 and 
a recent Mendelian randomization study has shown a 
causal link between IL-6 and psychosis.19 Dysglycaemia 
and inflammation may be associated with psychosis in 
a mediating relationship (inflammation leading to dys-
glycaemia leading to risk of psychosis), or a moderat-
ing relationship (inflammation associated with psychosis 
only in a pathway that also results in dysglycaemia).
We aimed to examine cross-sectional and longitu-
dinal associations between measures of  dysglycaemia, 
inflammation, and risk of  PEs/psychotic disorder 
in a large population birth cohort from the United 
Kingdom. We hypothesized that dysglycaemia would be 
associated with PEs/psychotic disorder, at younger ages 
than has been previously examined, after adjustments. 
We also aimed to test for mediation and/or moderation 
between inflammation and dysglycaemia for risk of 
PEs/psychotic disorder. Finally, we also examined the 
broader “metabolic syndrome” (MS) as an exposure, 
since there is research suggesting the intrinsic presence 
of  MS in FEP.20
Methods
Description of Cohort and Sample Selection
The Avon Longitudinal Study of Parents and Children 
(ALSPAC) birth cohort comprises 14,062 live births from 
mothers residing in (former) Avon County, southwest 
England, with expected dates of delivery between April 
1991 and December 1992 (http://www.bristol.ac.uk/
alspac/). Full cohort details appear elsewhere.21 A  fully 
searchable data dictionary is available at (http://www.bris.
ac.uk/alspac/researchers/data-access/data-dictionary/).
Our sample frame consisted of  participants that had 
data on all relevant variables (outcome measures, expo-
sures, and adjustment variables). Data for cross-sectional 
analysis between dysglycaemia and psychotic symptoms/
psychotic disorder at age 18 were available from 2627 
participants. Data for longitudinal analysis of  markers 
of  dysglycaemia at age 9 years and psychotic symptoms 
at age 12/18 years were available from 387 participants. 
The study received ethics approval from the ALSPAC 
Law and Ethics Committee and local research ethics 
committees. All participants provided written informed 
consent.
Laboratory Measures
Markers of Dysglycaemia (Ages 9 and 18 y)
We used the biochemical measurements of fasting plasma 
glucose (FPG), FI (ages 9 and 18 y), and 2-hour glucose 
tolerance (2hrGT) (age 9 y). Age 9 glycaemic data was 
derived from a smaller sub-study.22 Fasting samples were 
taken at 9 AM after a 10-hour fast (only water allowed 
during the fasting period). The 2hrGT test was obtained 
following the above procedure, with the addition of a 75 g 
oral bolus of sugary syrup at 9 AM, with blood sampled 
2 hours later.
IR was calculated from FPG and FI by using the com-
puterized, updated version of the Homeostasis Model 
Assessment for IR (HOMA2).
23 The algorithm gener-
ates a precise measurement of IR taking into account 
variations in hepatic and peripheral glucose resistance, 
increases in the insulin secretion curve for plasma glucose 
concentrations above 10 mmol/l and the contribution of 
circulating proinsulin.23
Cut-off for IR and IGT
In addition to a continuous HOMA2 variable, we used 
a binary “clinical IR” variable. There is no consensus-
agreed cut-off  for clinical IR in the literature using 
HOMA2,
24–27 since levels can be affected by multiple 
factors, including the study population.28 Proposed cut-
offs range from >1.026 through to 1.8025, with additional 
cut-offs suggested in-between these values.24,27 In lieu of 
an agreed cut-off, we chose to use the higher of the pro-
posed cut-offs (>1.79), to maximize the specificity of our 
results. However, as a sensitivity analysis, we used the 
75th centiles of the study populations (at ages 9 and 18 y) 
to define clinical IR (1.30 and 1.50, respectively) for each 
analysis.
In addition to the continuous 2hrGT variable, a binary 
variable was derived from the consensus-accepted clinical 
cut-off  for IGT (>7.8 mmol/l).29
MS at Age 18 Years
We constructed a binary MS variable using data avail-
able at age 18  years. There are numerous definitions of 
the MS, however, since our paper focuses on glycaemic 
abnormality, we used The World Health Organization 
(WHO) criteria,30 which emphasizes glycaemic abnor-
mality. The WHO criteria specifies either T2DM or IR/
IGT, plus 2 of either raised blood pressure (>140/90), 
dyslipidaemia (triglycerides [TG] >1.695  mmol/liter and 
high-density lipoprotein (HDL) < 0.9  mmol/l), cen-
tral obesity (waist:hip ratio >0.90 or body mass index 
[BMI] >30 kg/m2), and microalbuminuria (urinary albu-
min excretion ratio >20 µg/min or albumin:creatinine ratio 
> 30  mg/mmol). From the ALSPAC dataset, we were 
able to obtain, in addition to the measures of glycaemia 
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outlined above, TG, HDL, and BMI. Blood samples for 
HDL and TG were collected from fasting participants. 
As data were unavailable for some of the WHO criteria, 
we defined MS as presence of IR/IGT along with one 
of the following factors (HDL, TG, BMI), to maximize 
sensitivity.
As a sensitivity analysis, we created a second meas-
ure for MS from the International Diabetes Federation 
(IDF) consensus criteria31 which emphasizes obesity. The 
IDF criteria consists of central obesity, plus 2 of: raised 
TG (>1.7 mmol/l); reduced HDL (<1.03 mmol/l in males 
and <1.29  mmol/l in females); raised blood pressure 
(>130/85 mmHg); raised FPG (>5.6 mmol/l).
Inflammatory Markers (Ages 9 and 18 y)
We examined IL-6 (age 9 y) and CRP (ages 9 and 18 y). 
IL-6 was not available at age 18 years. Blood samples were 
collected from non-fasting participants at age 9  years, 
and fasting participants at age 18 years.
Measurement of Potential Confounders
Before analysis, we removed all participants with hsCRP 
>10,16 to address the potential confounder of ongoing/
recent infection/inflammatory disease. We also omitted 
those with previous use of anti-psychotic medication due 
to the risk of reverse causation. For cross-sectional analy-
ses at age 18 years, we adjusted for smoking (question-
naire data, coded categorically), BMI (clinic data, coded 
continuously), paternal social class at birth (questionnaire 
data, coded categorically), sex at birth (questionnaire 
data), ethnicity (questionnaire data, coded categorically), 
birthweight, and gestational age (clinic data, coded con-
tinuously). For analysis of MS, BMI was not adjusted for 
as this forms part of its diagnostic criteria. For our lon-
gitudinal analyses, we adjusted for BMI, paternal social 
class at birth, ethnicity, birthweight, and gestational age.
Outcome Measures
PEs (12 and 18 y)
PEs were identified through the face-to-face, semi-struc-
tured Psychosis-Like Symptom Interview (PLIKSi) con-
ducted by trained psychology graduates in assessment 
clinics and were coded according to the definitions and 
rating rules for the Schedules for Clinical Assessment in 
Neuropsychiatry, Version 2.0.32 Inter-rater reliability for 
the age 12 PLIKSi was κ = 0.75, with a test-retest relia-
bility of κ = 0.48,33 suggesting “fair” agreement. At age 
18  years, the PLIKSi has “good” inter-rater and test-
retest reliability (both κ = 0.8).34 PEs covering the 3 main 
domains of positive psychotic symptoms occurring either 
in the preceding 6 months (measured at age 12 y), or since 
age 12 years (measured at age 18 y) were elicited: halluci-
nations (visual and auditory), delusions (spied on, perse-
cuted, thoughts read, reference, control, grandiosity, and 
other), and thought interference (insertion, withdrawal, 
and broadcasting).
After cross-questioning, interviewers rated PEs as not 
present, suspected, or definitely present. For suspected 
or definite PEs, interviewers also recorded the frequency; 
affect, effects on social/educational/occupational func-
tion; help seeking; and attributions including fever, hyp-
nopompic/hypnogogic state, or illicit drugs. Cases of PEs 
in this study were defined only as individuals with defi-
nite PEs to help confirm a relatively “high-risk” group for 
later development of clinical psychosis. The comparator 
group was suspected/no PEs.
Psychotic Disorder (Age 18 y)
Psychotic disorder was defined by ALSPAC as the pres-
ence of PEs at least once per month in the preceding 
6 months, when symptoms were not attributable to fever/
sleep/drugs but caused significant distress and resulted in 
help-seeking from a professional source (general practi-
tioner, counselor, mental health team), or significantly 
disrupted social/occupational function. This opera-
tional definition has been examined and used in previous 
work.16,35
Statistical Analysis
A graphical display of the timeline of our included vari-
ables is outlined in table 1.
Cross-sectional and Longitudinal Relationships Between 
Dysglycaemia and PEs or Psychotic Disorder
Cross-sectional analyses examined the association 
between markers of dysglycaemia and PEs or psychotic 
disorder (age 18 y), while longitudinal analyses examined 
the association between markers of dysglycaemia (age 
9 y) and PEs or psychotic disorder (ages 12 and 18 y). 
Biomarker values that were not normally distributed (all 
except FPG) were natural log-transformed. Resultant 
variables were standardized (Z-transformed) so the ORs 
represent the increase in risk of PE per SD increase in 
exposure.
ORs and 95% CI for PEs were estimated using logistic 
regression. Biomarkers were modeled as both continuous 
Table 1. Longitudinal Timeline of Included Variables
Age (y) Exposure Outcome
Mediator/ 
Moderator
9 IR,FPG, FI, IGT IL-6, CRP
12 PEs
18 IR, FPG, FI, MS PEs, psychotic disorder CRP
Note: IR, insulin resistance; PEs, Psychotic Experiences; IL-6, 
interleukin-6; CRP, C-reactive protein; IGT, impaired glucose 
tolerance; MS, Metabolic Syndrome; FI, fasting insulin.
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and binary independent variables (as per the clinical cut-
off) in separate analyses. Quadratic terms were created sepa-
rately for all continuous variables and entered into a logistic 
regression model to simulate curvilinear regression, to test 
the linearity of relationships between PEs and biomarkers.
Cross-sectional and Longitudinal Relationships Between 
Dysglycaemia and Immune Activation
We completed univariable Pearson’s correlation analyses on 
metabolic and inflammatory biomarkers both cross-section-
ally (age 18 y) and longitudinally (ages 9 and 18 y). We com-
pleted multivariable analyses with adjustments (as described 
above) on biomarkers showing evidence of an association.
Mediation/Moderation Analyses Between 
Dysglycaemia, Inflammation and PEs/Psychotic 
Disorder
To test for moderation, we first completed a stratified 
analysis, in which the relationship between IL-6 (age 9 
y) and PEs or psychotic disorder (age 18 y) in groups 
with and without IR separately was examined, and then, 
under a logistic model whether there was an interaction 
between IL-6 (age 9 y) and IR (ages 9 and 18 y) (IL-6xIR) 
on the outcome of PEs or psychotic disorder. To test for 
mediation, we used the PROCESS add-on for IBM SPSS 
24.0 (available from http://www.afhayes.com). We tested 
for a significant indirect (mediation) effect for IR at age 
18 years between IL-6 at age 9 years and PEs/psychotic 
disorder at age 18 years.
Results
We included n = 2627 in our analyses. Table 2 presents 
clinical and biomarker characteristics of the sample at 
age 18 years. Our sample included n = 139 (5.2%) with 
definite PEs at age 12 years, n = 146 (5.4%) with definite 
PEs at age 18 years, and n = 37 (1.4%) with psychotic dis-
order at age 18 years.
Cross-sectional Association Between PEs and Markers 
of Dysglycaemia at Age 18
Using a categorical measure for IR, we found that IR was 
associated with PEs (adjusted OR = 2.32 [95% CI, 1.37–
3.97] P < .001). Using the continuous measure for IR, 
HOMA2 demonstrated a nonlinear, exponential relation-
ship with PEs (HOMA2 adjusted OR = 1.19 [1.01–1.43] 
P = 0.03; HOMA2 × HOMA2 adjusted OR = 1.08 [95% 
CI, 1.01–1.15] P = .02). FI demonstrated a linear relation-
ship with PEs (adjusted OR = 1.23 [1.03–1.47] P = .02). 
FPG and MS were not associated with PEs (table 3). No 
associations were demonstrated using the psychotic dis-
order outcome (supplementary table 1).
Longitudinal Association Between Markers of 
Dysglycaemia (Age 9 y) and PEs (Ages 12 and 18 y)/ 
Psychotic Disorder (Age 18 y)
There were no longitudinal associations between mark-
ers of dysglycaemia at age 9 years and PEs at ages 12 or 
18 years (table 4), or psychotic disorder (age 18 y) (sup-
plementary table 2).
Table 2. Characteristics of Sample at Age 18 y
Characteristic All Sample IR Absenta IR Presenta Test Statisticb P-value
Participants, n (%) 2627 (100) 2417 (92) 210 (8) —
Male sex, n (%) 1522 (49) 1403 (48.6) 119 (47.6) 0.10; P = .765
Father’s social class, n (%)
 I 143 (6) 136 (5.7) 7 (3.6) 9.27; P = .089
 II 929 (36) 861 (36.3) 68 (35.1)
 III 1098 (43) 1018 (42.9) 80 (41.2)
 IV 335 (13) 305 (12.8) 30 (15.5)
 V 63 (2) 68 (2.3) 134 (4.6)
White British ethnicity, n (%) 2574 (97) 2422 (97.9) 212 (97.7) 7.86; P = .453
BMI at 18 y, mean (SD), kg/m2 22.71 22.39 (3.42) 25.71 (5.56) 3.48 P < .001*
FPG at 18 y, mean (SD), mmol/l 5.03 (0.59) 5.00 (0.43) 5.34 (0.67) 3.49; P < .001*
HOMA2 at 18 y, mean (SD) 0.92 (0.73) 0.77 (0.32) 2.64 (1.52) 1.86; P < .001*
CRP at 18 y, mean (SD), mg/l 1.08 (1.41) 1.07 (1.40) 1.41 (1.62) 0.35; P < .001*
IL-6 at age 9 y, mean (SD), pg/ml 1.27 (1.59) 1.28 (1.62) 1.35 (1.41) 0.08; P = .531
CRP at age 9 y 0.68 (2.52) 0.69 (2.61) 0.68 (1.31) 0.01; P = .974
Birthweight, mean (SD), gram 3426.01 (549.86) 3431.02 (550.45) 3387.50 (525.38) 43.52; P = .249
Gestational age, mean (SD), wk 39.41 (1.84) 39.42 (1.83) 39.40 (1.70) 0.25; P = .841
Smoking at age 18 y, n (%) (current) 217 (6.86) 192 (6.6) 25 (10) 3.94; P = .043*
Note: BMI, body mass index; HOMA2, Homeostasis Model Assessment for Insulin Resistance; IL-6, interleukin-6; CRP, C-reactive protein.
*Denotes P < .05.
aHOMA2 score > 1.79.
bCategorical variables (sex, social class, ethnicity, smoking) were compared using a Chi-squared test, continuous variables (BMI, FPG, 
HOMA2, CRP, IL-6, Birthweight, Gestational Age) were compared using 2-tailed t test.
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Association Between IL-6, CRP, and Markers of 
Dysglycaemia
Cross-sectionally, CRP positively correlated with 2hrGT 
(age 9 y) (P < .01), HOMA2 (P < .01), and FI (P < .01) 
(age 18 y). Longitudinally, IL-6 (age 9 y) was positively cor-
related with HOMA2 (P < .01), FI (P < .01) and weakly 
negatively correlated with FPG (P < .01) (age 18 y). CRP 
(age 9 y) was positively correlated with HOMA2 (P < .01), 
Table 3. Cross-sectional Associations Between Metabolic Markers and PEs at Age 18
Predictor OR (95% CI) for Psychotic Outcomes
Unadjusted Model
Adjusted for Sex, Ethnicity,  
Social Class, BMIa and Smoking, 
Gestational Age, Birthweight
Definite PEs n OR (95% CI) P OR (95% CI) P
IR 2627 2.41(1.50–4.40) <.001* 2.32 (1.37–3.97) <.001*
HOMA2 2627 1.34 (1.17–3.18) .019* 1.19 (1.01–1.43) .034*
HOMA2 × HOMA2 2627 1.23 (1.06–3.09) .008* 1.08 (1.01–1.15) .021*
FPG 2627 0.89 (0.72–6.56) .670 0.96 (0.13–7.28) .966
FPG × FPG 2627 0.92 (0.82–1.06) .762 0.99 (0.82–1.19) .904
Fasting insulin 2627 1.36 (1.02–1.78) .019* 1.23 (1.03–1.47) .023*
Fasting insulin × fasting insulin 2627 1.07 (0.99–1.78) .201 1.02 (0.95–1.10) .526
Metabolic syndrome 2627 1.62 (0.77–3.39) .204 1.68 (0.71–3.97) .244
Note: BMI, body mass index; HOMA2, Homeostasis Model Assessment for Insulin Resistance; IR, insulin resistance; PEs, psychotic 
experiences. IR as categorical variable defined as HOMA2 >1.79. HOMA2, FPG, and Fasting Insulin presented as continuous variables.
aNot adjusted for in Metabolic Syndrome analysis.
*P < .05.
Table 4. Longitudinal Associations Between Metabolic Markers at Age 9 and PEs at Ages 12 and 18
Predictor OR (95% CI) for Psychotic Outcomes
Unadjusted Model
Adjusted for Sex, Ethnicity, 
Social Class, BMI
PE’s Age 12 y n OR (95% CI) P OR (95% CI) P
2hrGT (age 9 y) 387 0.51 (0.26–9.99) .048 0.77 (0.66–3.21) .102
2hrGT × 2hrGT (age 9 y) 387 0.92 (0.71–1.20) .527 0.91 (0.70–1.20) .507
HOMA2 (age 9 y) 357 1.05 (0.66–1.68) .712 1.10(0.79–1.53) .559
HOMA2 × HOMA2 (age 9 y) 357 0.89 (0.11–7.01) .913 0.84 (0.10–7.00) .875
Fasting insulin (age 9 y) 357 1.14 (0.62–2.10) .683 1.11 (0.70–1.91) .721
Fasting insulin × fasting insulin (age 9 y) 357 0.85 (0.54–1.33) .480 0.84 (0.54–1.31) .447
FPG (age 9 y) 357 1.42 (0.51–4.00) .503 1.56 (0.45–5.44) .478
FPG × FPG (age 9 y) 357 0.42 (0.04–4.20) .458 0.41 (0.04–4.18) .451
IR (age 9 y) 357 1.25 (0.16,9.76) .826 1.17 (0.14–9.80) .881
IGT (age 9 y) 395 0.46 (0.17–1.21) .122 0.72 (0.24–2.20) .572
PE’s at age 18 y
2hrGT (age 9 y) 337 1.08 (0.49–2.36) .245 1.06 (0.48–2.33) .890
2hrGT × 2hrGT (age 9 y) 337 0.62 (0.28–2.36) .857 0.61 (0.27–1.48) .229
HOMA2 (age 9 y) 352 1.05 (0.66–1.68) .834 0.59 (0.28–1.25) .171
HOMA2 × HOMA2 (age 9 y) 352 1.18 (0.66–2.03) .754 1.12 (0.41–3.11) .816
Fasting insulin (age 9 y) 352 0.66 (−0.33 to 1.23) .178 0.73 (0.37–1.43) .355
Fasting insulin × fasting insulin (age 9 y) 352 0.88 (0.48–1.63) .684 0.88 (0.48–1.61) .676
FPG (age 9 y) 352 - - - -
FPG × FPG (age 9 y) 352 - - - -
IR (age 9 y) 352 1.25 (0.16–9.76) .699 - -
IGT (age 9 y) 337 0.82 (0.27–2.50) .734 0.93 (0.27–3.25) .929
Note: 2hrGT, 2-hour glucose tolerance; BMI, body mass index; HOMA2, Homeostatic Measurement for Insulin Resistance; IR, insulin 
resistance; PEs, psychotic experiences; IGT, impaired glucose tolerance. IR and IGT as categorical variable defined as HOMA2 > 1.79 
and IGT > 7.8 mmol. HOMA2, FPG, and Fasting Insulin presented as continuous variables.
- Unable to compute due to small n.
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FI (P < .01) and weakly negatively correlated with FPG 
(P = .03) (age 18 y; supplementary table 3). In multivariable 
analyses, evidence for a longitudinal association between 
serum IL-6 levels (age 9 y) and IR (age 18 y) remained after 
adjusting for potential confounders; adjusted OR  =  1.65 
(95% CI, 1.01–2.68) P = .04 (supplementary table 4).
Mediation and Moderation Analyses Between 
Dysglycaemia, Inflammation and PEs/Psychotic 
Disorder
Results for Moderation Analysis. Three hundred 
twenty-six individuals (14%) met the criteria for IR at 
age 18 years. In univariable analyses, IL-6 (age 9 y) cor-
related with PEs (age 18) (P = .02). CRP (ages 9 and 18 y) 
did not correlate with PEs (age 18 y). Table 5 outlines the 
results of our stratification analysis. IL-6 was associated 
with PEs in the strata with IR (adjusted OR = 2.34 [95% 
CI, 1.02–5.33] P = .03), but not in the strata without IR 
(adjusted OR = 1.10 [95% CI, 0.84–1.45] P = .47). Our 
interaction analysis demonstrated an interaction between 
IL-6 (age 9 y) and IR (age 18 y) for PEs (age 18 y) (OR 
for interaction term = 2.18 [95% CI, 1.06–4.49] P = .03). 
There was no evidence for an interaction between IL-6 
and IR (age 9 y) for PEs (age 18 y) (OR for interaction 
term = 1.29 [95% CI, 0.69–2.19] P = .49). Using the psy-
chotic disorder outcome, IL-6 (age 9 y) was associated 
with psychotic disorder (age 18 y) in the strata without 
IR (adjusted OR = 1.63 [95% CI, 1.08–2.46] P = .02), but 
the effect was significantly stronger in the strata with IR 
(adjusted OR = 4.71 [95% CI, 1.38–16.07] P = .01) (OR 
for interaction term = 3.23 [95% CI, 1.08–11.65] P = .04; 
supplementary table 5).
Results for Mediation Analysis. There was no evidence 
of an indirect (mediation) effect, using IR (age 18 y) as the 
mediator variable between IL-6 (age 9 y) and PEs (age 18 y): 
coefficient <0.001; SE = 0.005; P = .982. Similar results 
were obtained using HOMA2 (age 18 y) as the potential 
mediator: coefficient = 0.01; SE = 0.01; P = .11. For the 
psychotic disorder outcome, there was no evidence of an 
indirect (mediation) effect using IR (age 18 y) as the medi-
ator variable: coefficient = 0.01; SE = 0.01; P = .46.
Results for Sensitivity Analyses. The results tables for 
our sensitivity analyses for both the 75th centile-defined 
cut-off  for IR, and for IDF-defined MS, are presented 
in the sensitivity analysis section of the supplementary 
data (supplementary tables 6–10). All associations dem-
onstrated in our primary analyses were retained in the 
sensitivity analyses.
Discussion
Main Findings
In this secondary analysis of a large birth cohort, we 
examined whether dysglycaemia is associated with PEs/
psychotic disorder at an earlier age than previous research 
has examined. We also investigated whether some of the 
known immune associations with psychosis may be part 
of a wider relationship involving dysglycaemia. Firstly, we 
hypothesized that dysglycaemia would be associated with 
PEs. After adjustments for confounders, we found that 
the continuous measure for HOMA2 was non- linearly 
(exponentially) associated with PEs, and the binary 
measure for clinical IR was even more strongly associ-
ated with PEs, at age 18 years. Additionally, the HOMA2 
cut-off  for our 75th centile-defined IR, which was lower 
(>1.50) than our primary cut-off  (>1.79), demonstrated a 
less-strong association with PEs at age 18 years. Together, 
this provides face validity to our results, considering the 
non-linear (exponential) association between the contin-
uous HOMA2 measure and PEs at age 18  years. There 
were no longitudinal associations between dysglycaemia 
at age 9 years and later PEs, or when using the outcome 
“psychotic disorder,” though the sample of participants 
at age 18 years with psychotic disorder was small thus the 
power of such analyses was limited.
A shared disease process may link dysglycaemia, 
immune activation and psychotic symptoms.8,36 Previous 
work using the same birth cohort has found that 
Table 5. OR for IL-6 (Age 9 y) and PE (Age 18 y) Stratified by IR
Odds Ratio (95% CI) for PEs at 18 yrs
Adjusted for Sex, Ethnicity, Social 
Class, BMI, Smoking, Gestational 
Age, Birthweight
Group/Predictor n OR (SD) P OR (SD) P
IR absent at 18 y
 IL-6 at age 9 y 2301 1.12 (0.83–1.43) .338 1.10 (0.84–1.45) .471
IR present at 18 y
 IL-6 at age 9 y 326 2.45 (1.24–4.84) 0.009* 2.34 (1.02–5.33) .03*
Note: BMI, body mass index; IR, insulin resistance; PEs, Psychotic Experiences; IL-6, interleukin-6.
*P < .05.
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childhood IL-6 is longitudinally associated with PEs at 
age 18 years.16 We found that IL-6 correlates with mark-
ers of dysglycaemia longitudinally. We also found that, 
using both cut-offs for IR, there is a statistical interaction 
between IL-6 and IR for the outcome of both PEs and 
psychotic disorder at age 18 years. Interaction analyses, 
particularly of quantitative pattern as described here, 
are fraught with limitations and are historically difficult 
to replicate,37 thus our findings regarding moderation 
should be considered tentatively. Nonetheless, our results 
may indicate a shared pathophysiological process involv-
ing metabolic and inflammatory alterations in at least a 
subset of individuals who develop PEs, although extrap-
olating findings of statistical interaction to infer infor-
mation about biological mechanisms is problematic.38 
Biological plausibility may exist via a disruption in the 
PI3K/mTOR/AKT pathway, which is involved in insulin 
sensitivity, neuronal growth and axon elongation, dopa-
mine regulation, and the innate and adaptive immune 
systems,39–41 and has previously been implicated as a 
potential mechanism linking schizophrenia and T2DM.42 
Additionally, common risk factors for both psychosis and 
dysglycaemia include intra-uterine insults (trauma, infec-
tion, gestational diabetes) and early-life distress, both of 
which may involve inflammatory processes,43,44 contribut-
ing to an early-programming model of illness.
Our mediation analysis suggests that IR does not 
mediate the association between IL-6 and PEs/psychotic 
disorder. However, this mediation analysis was imperfect 
as we were unable to fit the mediator variable longitudi-
nally in-between the exposure and outcome. We were also 
unable to test mediation reciprocally, ie, with IL-6 as a 
mediator between IR and PEs/psychotic disorder. Future 
work may seek to attempt to address these issues.
Interestingly, PEs were not associated with the binary 
variable of MS, either by WHO (dysglycaemia-centric) or 
IDF (obesity-centric) criteria. This finding may provide 
some evidence that the driver of metabolic abnormality 
in those with PEs, at least initially, is IR, and may fos-
ter increased emphasis on the use of WHO criteria for 
patients with psychosis. Several recent meta-analyses8,45,46 
have shown a relationship between lipid metabolism and 
FEP. Our findings suggest that IR may be upstream of the 
wider MS, which would align with endocrine literature, 
that supports IR as an upstream driver of lipid dysfunc-
tion and other elements associated with chronic psycho-
sis, such as cardiovascular disease and hypertension.47
We found no longitudinal associations between markers 
of dysglycaemia (age 9 y) and PEs (ages 12 and 18 y), after 
adjustments. These findings give weight to the hypothesis 
that immune dysfunction may be upstream of dysglycae-
mia in its relationship with psychosis.48 While a relatively 
smaller sample size for the longitudinal analysis may have 
resulted in type II error, another interpretation is that an 
abnormal metabolic process (measured by IR) that con-
tributes to risk of PEs may be undeveloped by age 9 years.
Strengths and Limitations
There are several strengths to our work. Firstly, to our 
knowledge this is the first study to investigate that met-
abolic abnormality might be present in those with PEs, 
and that it may be linked to immune activation. Secondly, 
the ALSPAC cohort provided the opportunity to con-
duct analyses on a relatively large and well characterized 
cohort and permitted longitudinal analyses. Thirdly, we 
were able to consider detailed potential confounders and 
minimize possible reverse causality secondary to the use 
of antipsychotic medication.
There are important limitations that should be taken 
into our account, meaning our results should be inter-
preted with caution. Firstly, IL-6 is but one cytokine in 
the constellation of immune activation. Future studies 
should include multiple pro and anti-inflammatory mark-
ers for a comprehensive understanding of the immune 
changes linking dysglycaemia and PEs. Additionally, 
the sample available for different analyses differed due 
to availability which may introduce a source of bias. 
Furthermore, since we included only those participants 
who received testing for all the variables we analyzed, 
selection bias may also be factor. We were also limited by 
the variables available for analysis; an ideal study would 
include a measure of IL-6 at age 18 years. Also, since a 
number of variables featured in the WHO classification30 
for MS were unavailable, we aimed to maximize sensitiv-
ity potentially at the expense of specificity in our analysis. 
However, our sensitivity analysis using the IDF defini-
tion31 featured the whole criteria, and the results did not 
differ. In addition, clinical cut-offs for IR measured using 
HOMA2 may be problematic.
28 We attempted to address 
this limitation by using the highest of the proposed cut-
offs (to increase specificity), and to define a population-
based cut-off  using the 75th centile. Furthermore, while 
most biochemical tests were sampled in the fasting state, 
inflammatory markers at age 9  years were sampled in 
the non-fasting state, which may increase measurement 
error. Measurement error, if  non-differential as is likely 
to be the case here, can introduce a bias towards the null, 
so the results for IL-6 may be underestimated. In addi-
tion, while longitudinal studies34 have shown PEs to be 
a robust estimator for a later diagnosis of psychotic ill-
ness, we did not examine a clinical sample with diagnosed 
schizophrenia. We attempted to manage this limitation 
by including the psychotic disorder outcome as a second-
ary analysis, though the power of such analyses were lim-
ited. Interestingly, depression has also shown significant 
associations with childhood immune processes16 and dys-
glycaemia.48 Future research should longitudinally exam-
ine the association and direction of association between 
inflammation, dysglycaemia, and depression. Finally, 
while we were able to adjust for multiple possible con-
founders in our analysis, we were unable to account for 
the possible contribution of perceived stress and chronic 
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activation of the hypothalamic-pituitary axis in our find-
ings. Future research may seek to address this.
Implications and Future Directions
Our results provide evidence that even before the onset 
of clinical psychosis, some patients may have an active 
process involving IR and inflammation, which may pre-
dispose to further metabolic dysfunction. It is possible 
that inflammation and metabolic risk factors interact 
to increase risk of psychosis in some people. That IR is 
associated with PE’s even after controlling for potential 
confounding factors is important and may provide evi-
dence for clinicians and those involved in clinical guide-
line formation, to the potential need for more sensitive 
examination of baseline metabolic function at FEP. As 
some second-generation antipsychotics are diabetogenic, 
careful selection of medication accounting for sensitive 
metabolic dysfunction may reduce the risk of iatrogenic 
“toppling” into clinical type-2 diabetes.
Supplementary Material
Supplementary material is available at Schizophrenia 
Bulletin online.
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